Abstract 45P
Background
Pathologic complete response (pCR) is often utilized as a surrogate marker for overall survival in breast cancer. Significant differences in pCR rates are reported in many studies depending on the biological tumor profile and molecular classification. Based on our observations we hypothesize that few breast cancer patients are less likely to achieve pCR after neoadjuvant chemotherapy (NACT). The role of demographic variables in predicting pCR is still not clear. The aim of this study was to evaluate various demographic factors which could impact pCR rates.
Methods
A prospective analysis of 1246 patients with breast carcinoma who had undergone neoadjuvant chemotherapy (NACT) followed by surgery was done from June 2020 to December 2022. Demographic, surgical, and pathological data were collected on completion of therapy. Categorical variables were analyzed using χ2 or Fisher’s exact test and continuous data were analyzed using t-tests. Multiple linear regressions were used to study interactions between various demographic factors and pCR. Statistical analysis was done using SPSS v25.
Results
A total of 1324 patients were offered NACT, of which 1246 (94.1%) who underwent resection post-NACT were included in the analysis. Overall, 275 (22.1%) patients had pCR. 39 (14.2%) in ER+/HER2- group, 131 (47.6%) in HER2+ group; and 105 (38.2%) in ER-/HER2- group had pCR. Univariate analysis showed significant association between age <50 years, low body-mass index, and ability to achieve pCR. However, women with obesity had higher odds of residual disease (OR = 0.191 [0.029-1.157]; p=0.076). The results were consistent even after controlling for confounding variables such as grade, receptor status, and clinical T and N stages.
Conclusions
Younger age can predict a pCR and is an independent prognostic factor for locoregional recurrence in locally advanced breast cancer patients after NACT. Obesity is a risk factor for failure to achieve PCR in women undergoing NACT. The contrary was observed in non-obese patients as they had higher odds of achieving PCR. Studies with larger groups are needed to validate this observation. Further studies evaluating the role of BMI in drug resistance would be valuable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract